Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life

Deprez, V.; Monnier, Laure Le; Sobhy-Danial, Jean-Marc; Grados, Franck; Henry-Desailly, Isabelle; Salomon-Goëb, Sarah; Rabin, Thibault; Ristic, Sanja; Fumery, Mathurin; Fardellone, Patrice; Goëb, Vincent

doi:10.3390/jcm9103319

Cited by 7 publications

(2 citation statements)

References 29 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Efficacy was observed despite the disease being active, persistent, and treatment-resistant at baseline. Despite the small sample size, the results of this study are consistent with those reported in the literature from RCTs and other realworld cohorts demonstrating an improvement in all clinimetric scores and activity indexes in both bDMARD-naïve and failure RA patients (13)(14)(15)(16)(17)(18).…”

Section: Original Papersupporting

confidence: 90%

“…Extensive observational research on JAKinhibs in RA is expanding, and a substantial amount of data from real-world clinical settings is now accessible. Several of these data are limited to a 12-month follow-up period (13)(14)(15)(16)(17)(18). Consequently, the primary objectives of the present study were to assess the efficacy, as measured by DAS-28 and SDAI, and safety of tofacitinib and baricitinib during a of follow-up up to 24 months in patients with RA treated in a real-world setting in Southern Italy.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy

et al. 2022

View full text Add to dashboard Cite

The primary objectives of the study were to evaluate the efficacy and safety of tofacitinib and baricitinib up to 24 months of follow-up in patients with rheumatoid arthritis (RA) treated in Southern Italy. Patients’ data, activity index, and clinimetric scores were collected at baseline (T0), six (T6), twelve (T12), and twenty-four (T24) months following treatment initiation. At six, twelve, and twenty-four months, adverse events and treatment cessation were also recorded. Sixty-eight patients (mean age: 62.2±10.9 years; mean RA duration: 15±9.6 years) were enrolled over a period of 12 weeks. At baseline, twenty-four patients (35.3%) were treated with tofacitinib, and forty-four patients (64.7%) were treated with baricitinib. The baseline mean disease activity was moderate as measured by DAS28- ESR (5.0±1.0), DAS 28 CRP (4.69±0.94), and SDAI (26.87±10.73) score. Before beginning JAKinhibs therapy, thirty-two patients (61.8%) were taking bDMARDs, while the remaining thirty-six (38.2%) were bDMARDs-naïve. The 24-month retention rate for JAKinhibs was 91.1%. Six months after beginning treatment with JAKinhibs, a statistically significant improvement was observed in all evaluated activity indices and clinimetric scores. Improvement was confirmed during the 12- and 24-month follow-up evaluations. The positive correlation between baseline-T6 SDAI delta and discontinuation of JAKinhibs (p=0.02) suggests that RA worsening in the first six months may be a predictor of therapy withdrawal. Patients with RA responded favorably to tofacitinib and baricitinib in this prospective, real-world study from a single center in Southern Italy. Efficacy was observed despite an underlying persistent and treatment-resistant disease.

show abstract